ProShare Advisors’s Disc Medicine IRON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$363K Sell
4,959
-729
-13% -$50.1K ﹤0.01% 1299
2026
Q1
$364K Sell
5,688
-539
-9% -$37.4K ﹤0.01% 1236
2025
Q4
$494K Buy
6,227
+1,039
+20% +$87.8K ﹤0.01% 1135
2025
Q3
$343K Sell
5,188
-1,157
-18% -$68.8K ﹤0.01% 1334
2025
Q2
$336K Sell
6,345
-155
-2% -$7.28K ﹤0.01% 1370
2025
Q1
$323K Sell
6,500
-466
-7% -$25.9K ﹤0.01% 1361
2024
Q4
$442K Buy
6,966
+1,458
+26% +$84.3K ﹤0.01% 1348
2024
Q3
$271K Buy
+5,508
New +$259K ﹤0.01% 1530
2024
Q2
– Sell
-3,385
Closed -$211K – 1921
2024
Q1
$211K Buy
+3,385
New +$219K ﹤0.01% 1640

Other funds holding IRON

ProShare Advisors's IRON Position: Q2 2026 in Review

ProShare Advisors reduced its Disc Medicine (IRON) stake by 13% in Q2 2026, selling an estimated $50.1K and leaving 4,959 shares worth $363K. The position accounts for ﹤0.01% of the portfolio, ranked #1299.

ProShare Advisors first reported a position in IRON in Q1 2024 and has held it in 9 quarters since. The position peaked at $494K in Q4 2025. 216 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • ProShare Advisors held 4,959 shares of Disc Medicine worth $363K as of Q2 2026.
  • ProShare Advisors sold 729 Disc Medicine shares in Q2 2026, an estimated $50.1K.
  • Disc Medicine made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1299 holding.
  • ProShare Advisors first reported a position in Disc Medicine in Q1 2024 and has held it in 9 quarters since.
  • ProShare Advisors's Disc Medicine position peaked at $494K in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.